Protein-bound polysaccharide-K augments the anticancer effect of fluoropyrimidine derivatives possibly by lowering dihydropyrimidine dehydrogenase expression in gastrointestinal cancers

ELJI MEKATA¹, SATOSHI MURATA¹, HIROMICHI SONODA¹, TOMOHARU SHIMIZU¹, TOMOKO UMEDA¹, HISANORI SHIOMI¹, SHIGEYUKI NAKA¹, HIROSHI YAMAMOTO¹, HAJIME ABE¹, TAKEO EDAMATSU², AYAKO FUJIEDA², MASAKI FUJIOKA², TSUTOMU WADA² and TOHRU TANI¹

¹Department of Surgery, Shiga University of Medical Science, Seta Tsukinowa-cho, Otsu, Shiga 520-2192; ²Biomedical Research Laboratories, Kureha Corporation, Shinjuku, Tokyo 169-8503, Japan

Received July 18, 2013; Accepted September 9, 2013

DOl: 10.3892/or.2013.2788

Abstract. Protein-bound polysaccharide-K (PSK) enhances the antitumor effect of anticancer drug when used clinically in combination with such drugs. PSK is known to act by immune-mediated mechanisms; however, the relationship between PSK and metabolic enzymes of anticancer drugs is unknown. We used the collagen gel droplet-embedded culture drug sensitivity test (CD-DST) clinically to evaluate the sensitivity of anticancer drugs. In the present study, we modified the CD-DST by adding peripheral blood mononuclear cells (PBMCs) (immuno-CD-DST) and examined the antitumor effect of PSK in combination with anticancer drugs. First, HCT116 human colon cancer cells were cultured with PSK and 5-fluorouracil (5-FU) or 5'-deoxy-5-fluorouridine (5'-DFUR) in the presence or absence of PBMCs, and the antiproliferative effects were compared. In the presence of PBMCs, PSK augmented the inhibitory effects of 5-FU and 5'-DFUR on HCT116 cell proliferation. Next, using human gastric cancer and colon cancer cell lines, the effects of PSK on mRNA expression of various metabolic enzymes of fluoropyrimidines: dihydropyrimidine dehydrogenase (DPD), thymidylate synthase, thymidine phosphorylase and orotate phosphoribosyl transferase, were examined by real-time PCR. PSK significantly enhanced DPD mRNA expression in all of the cancer cell lines tested, but not those of the other enzymes. Addition of IFN-α and TRAIL, cytokines known to inhibit DPD expression, to the cultures reduced DPD mRNA expression in the cancer cells. When PBMC samples collected from healthy volunteers were cultured with PSK, IFN-α mRNA expression increased in 3 of the 5 PBMC samples, while TRAIL mRNA expression was unchanged. The present results propose the possibility that PSK induces PBMCs to express IFN-α which inhibits DPD expression, and consequently augments the antitumor effect of 5-FU or 5'-DFUR. Immuno-CD-DST is useful for evaluating drugs with immunological mechanisms of action.

Introduction

With recent advances in the development of molecular-targeted anticaner agents, it is now possible to identify patients who are likely to respond to treatment and those who are not. For drugs such as cetuximab and Herceptin, pre-treatment tests to examine the expression of various marker molecules have become routine (1,2). Unfortunately, this type of testing is only available for a small number of anticancer drugs. For the majority of cancer chemotherapies, there are no markers to predict response in individual patients, which adds difficulties in designing protocols for clinical trials. In the clinical setting, the explanation for chemotherapy to patients relies mainly on statistical information, which is often not sufficiently convincing. In our department, in order to conduct chemotherapies with patient confidence and plan a precise treatment policy for each patient, we aim at individualized treatment by testing the sensitivity of tumor cells to chemotherapeutic agents using the collagen gel droplet-embedded culture drug sensitive test (CD-DST), a test that simulates physiological conditions. Although the CD-DST may be sufficient to evaluate chemotherapeutic agents alone, in our clinical practice we encounter many patients who are treated with a combination of chemotherapeutic and immunotherapeutic agents such as biological response modifiers (BRMs).
In these cases, an evaluation method that reflects the immune capability of patients is needed. For this purpose, we modified the CD-DST by adding the peripheral blood mononuclear cells (PBMCs) of patients to the test system and incubating for long periods (designated immuno-CD-DST). Using this method, we attempted to evaluate the effect of combination therapy with BRMs and fluoropyrimidine anticancer agents, and study the effect of BRMs on intra-tumoral enzymes in the presence of PBMCs.

Regarding immunotherapeutic agents, we selected to study protein-bound polysaccharide K (PSK) which is known to be a BMR. PSK has been reported to enhance the effects of anticancer drugs, particularly fluoropyrimidine derivatives, against gastric, colorectal and small cell lung cancer. Currently, PSK is used clinically in Japan and Taiwan. In Japan, the efficacy of combined therapy with PSK and fluoropyrimidine derivatives as postoperative adjuvant therapy for gastric cancer has been reported (3). Clinical trials have also been conducted on colon, rectal (4) and lung cancer (5), and PSK was shown to enhance the effects of fluoropyrimidine derivatives. PSK is a substance extracted from the fungus *Coriolus versicolor*, and is composed of protein and polysaccharide with a β-1,4 glucan structure. The approximate molecular weight is 100 kDa. Various mechanisms of the antitumor action of PSK have been reported, including immunomodulation (enhancing NK cell, cytotoxic T lymphocyte and lymphokine-activated killer cell activities) and direct damage to cancer cells (6,7). Recent study has shown that PSK acts as a TLR2 agonist to induce immunomodulatory effects (8). However, there is no report on how PSK enhances the effects of fluoropyrimidine derivatives, although the mechanisms of action and metabolic pathways of anticancer agents belonging to the fluoropyrimidine family have been elucidated. Inside the tumor cells, 5-fluorouracil (5-FU) is converted to 5-fluoro-2′-deoxyuridine by thymidine phosphorylase (TP), and is further converted to 5-fluoro-2′-deoxyuridine 5′-monophosphate by thymidine kinase, consequently inhibiting the DNA synthesizing enzyme thymidylate synthase (TS). Moreover, orotate phosphoribosyl transferase (OPRT) converts 5-FU to 5-fluoro-uridine monophosphate, thereby inhibiting DNA and RNA syntheses. On the other hand, dihydropyrimidine dehydrogenase (DPD) is known to metabolize 5-FU to the inactive form dihydrofurouracil. Therefore, the lower the activity of DPD, the higher is the activity of 5-FU.

In the present study, we examined whether the addition of PBMCs to the CD-DST alters the antiproliferative effect of PSK combined with 5-FU or 5′-DFUR against tumor cells. Furthermore, focusing on the possible mechanism of how PSK enhances the effect of fluoropyrimidines, we also examined the effect of PSK on the expression of the metabolic enzymes of fluoropyrimidines (DPD, TP, TS and OPRT). The present study reports for the first time the possibility that inhibition of DPD expression by PSK may be a mechanism by which PSK enhances the effect of fluoropyrimidines, as shown experimentally using the immune-CD-DST.

**Materials and methods**

**Materials.** 5-FU was purchased from Kyowa Hakko Kogyo, Co., Ltd. (Tokyo, Japan). 5′-DFUR was a gift from Chugai Pharmaceutical Co., Ltd. (Tokyo, Japan). PSK was manufactured at Kureha Corp. (Tokyo, Japan) and dissolved in Dulbecco’s phosphate-buffered saline (Gibco-BRL, Grand Island, NY, USA). In each experiment, freshly prepared PSK solution was used. Human gastric cancer cell lines (GCIY and MKN45) and human colon cancer cell lines (HCT116 and WiDr) were obtained from ATCC (Manassas, VA, USA). Cells were maintained in RPMI-1640 medium (Gibco-BRL) supplemented with 10% fetal bovine serum (FBS) (Life Technologies, Milan, Italy) and non-essential amino acids (Sigma, St. Louis, MO, USA). Recombinant IFN-α and TNFα were purchased from Humanzyme Inc. (Chicago, IL, USA) and TRAIL from PeproTech (Rocky Hill, NJ, USA).

**Peripheral blood mononuclear cells.** Blood donors were selected from healthy volunteers registered at the Department of Surgery, Shiga University of Medical Science, and Biomedical Research Laboratories, Kureha Corp. All donors provided written informed consent. Lymphoprep (Axis-Shield, Oslo, Norway) was used to isolate PBMCs from peripheral blood.

**Tumor cell proliferation assay.** Tumor cell proliferation assay was conducted using the CD-DST as previously described (9). Briefly, HCT-116 cells were cultured in RPMI-1640 medium supplemented with 10% FBS (10% FBS-RPMI) at 37°C in a 5% CO₂ atmosphere. Using a Collagen Gel Culture kit (Nitta Gelatin Inc., Osaka, Japan), each cell line was mixed in molten collagen at a final density of 2x10⁶ cells/ml. After solidification, the collagen gel-embedded cells were overlaid with 10% FBS-RPMI containing 5-FU (0.3 µg/ml) or 5′-DFUR (3 µg/ml), PSK (0, 100 or 300 µg/ml) and PBMCs (none or 4 times the number of cancer cells) and cultured stationarily at 37°C in 5% CO₂ atmosphere for 144 h. At the end of the incubation, Neutral red was added to each well at a final concentration of 50 µg/ml, and colonies of HCT-116 cells in the collagen gel droplet were stained for 2 h. The cells were then fixed with 10% neutral-buffered formalin. Images of the stained gel were acquired with a video microscope (VH-5910; Keyence, Osaka, Japan), and the optical density was measured, which indicated the cell proliferation rate. Sensitivity was expressed as T/C (%), where T is the image optical density of the treated group and C is that of the control.

**Collagen gel culture**

**Experiment 1. Expression of fluoropyrimidine metabolic enzymes in tumor cells.** Cells were pre-cultured in 10% FBS-RPMI at 37°C in a 5% CO₂ atmosphere. Using a Collagen Gel Culture kit, each cell line was mixed with molten collagen at a final density of 2x10⁶ cells/ml, and then spread on a culture dish (φ=100 mm; Asahi Glass Co., Ltd., Tokyo, Japan). After solidification, the collagen gel-embedded cells were overlaid with 10% FBS-RPMI containing PSK (0, 100 or 300 µg/ml) and PBMCs (none or 4 times the number of cancer cells) and cultured stationarily at 37°C in a 5% CO₂ atmosphere for 144 h. At the end of the incubation, the culture was treated with 1% collagenase (Sigma) for 15 min at 37°C and cells were recovered. Total RNA was extracted from the cells using RNeasy Mini kit (Qiagen Inc., Valencia, CA, USA). Messenger RNA expression of fluoropyrimidine metabolic enzymes was measured quantitatively by real-time PCR.
Experiment 2. Effect of addition of cytokines on DPD expression. Using a Collagen Gel Culture kit, cells were embedded in collagen gel at a final density of 8x10^5 cells/ml. After solidification, the collagen gel-embedded cells were overlaid with 10% FBS-RPMI containing various human recombinant cytokines and incubated at 37˚C in a 5% CO₂ atmosphere for 72 h. At the end of the incubation, collagenase was added to recover the cells from the collagen gel, and total RNA was extracted using FastPure RNA kit (Takara Bio Inc., Shiga, Japan). Messenger RNA expression of cytokines was quantitatively measured by real-time PCR.

Real-time polymerase chain reaction. From the total RNA, cDNA was synthesized using the PrimeScript RT reagent kit (Takara Bio). Using the cDNA as template, real-time PCR was performed with SYBR Premix Ex Taq II (Takara Bio). The quantity of expression of each gene was normalized to that of GUSB, GAPDH or β-actin gene. The gene expression level was expressed relative to the expression level of the control (=1). The primers used are shown in Table I. The primer for GUSB (HA067813) was purchased from Takara Bio.

Results

PSK augments the antiproliferative effect of 5-FU and 5'-DFUR in the presence of PBMCs. We modified the CD-DST that we developed for evaluating the sensitivity of tumors to chemotherapeutic agents (9), by adding PBMCs to the culture system (immuno-CD-DST) (Fig. 1). Using this system, we examined whether addition of PSK, which is known to have an immunomodulatory activity, affects the antitumor effect. The concentrations of 5-FU and 5'-DFUR were the same as used in our previous study using the CD-DST (9). We embedded the human colon cancer cell line HCT116 in collagen, and cultured the collagen gel-embedded cells with PSK and 5-FU or 5'-DFUR in the presence or absence of PMBCs for 144 h. The addition of PSK suppressed cell proliferation both in the presence and in the absence of PMBCs, but the suppression was stronger in the presence of PMBCs. When 5-FU together with PSK were added, the antiproliferative effect was enhanced both in the presence and in the absence of PMBCs, but the effect was the strongest in the presence of PMBCs (Fig. 2A). Likewise, 5'-DFUR showed similar results (Fig. 2B).

PSK reduces DPD mRNA expression in gastrointestinal cells. Based on finding that the antiproliferative effect of
fluoropyrimidine derivatives is the strongest with the addition of PSK in the presence of PMBCs, we next examined the effects of PMBCs and PSK on the expression of enzymes (DPD, TS, TP and OPRT) associated with the metabolism of fluoropyrimidine derivatives. When collagen gel-embedded gastric cancer cell lines (GCIY and MKN45) and colon cancer cell lines (HCT116 and WiDr) were incubated with PSK, no marked changes in DPD mRNA expression were observed. In contrast, when the collagen gel-embedded cancer cells were incubated with PSK in the presence of PBMCs, DPD mRNA expression was reduced in both the gastric and colon cancer cell lines (Fig. 3). Although no consistent changes in RNA
expression of the other fluoropyrimidine metabolic enzymes TS, TP and OPRT, were observed by the addition of PSK and PBMCs, TS expression in HCT-116 cells and TP expression in GCIY cells were strongly suppressed (data not shown).

Since the PSK-induced suppression of DPD mRNA expression was consistently lower in the presence of PBMCs than in the absence of PBMCs in all the cell lines examined, we further examined the effect of PSK on DPD expression.

**IFN-α and TRAIL reduce DPD mRNA expression in GCIY and HCT-116 cells.** IFN-α and TRAIL have been reported to suppress DPD expression in cells (10,11). Using CD-DST, we examined whether addition of these cytokines suppresses DPD expression in GCIY and HCT-116 cell cultures. In both cell lines, DPD expression was reduced by incubation with IFN-α or TRAIL (Fig. 4A and B). Since TRAIL belongs to the TNF-α family, we also examined the effect of TNF-α on DPD expression but observed no changes in DPD mRNA expression (data not shown).

**PSK possibly induces IFN-α mRNA expression in PBMCs.** Next, we examined whether the expression of IFN-α and TRAIL is induced in PBMCs obtained from healthy volunteers when cultured in the presence or absence of PSK. IFN-α mRNA expression in PBMCs was increased by 4-fold in 1 of 5 subjects, and by 1.4- to 1.5-fold in 2 of 5 subjects (Fig. 5A). In contrast, TRAIL expression in PBMCs was reduced by 0.5- to 0.6-fold in 2 of 5 subjects, with no marked changes (Fig. 5B).

**Discussion**

In the present study, we developed an experimental culture model by adding human PBMCs in suspension to collagen gel droplet-embedded cancer cells (immuno-CD-DST), and used this model to examine whether PSK affects the anti-proliferative activity of the fluoropyrimidine derivatives, 5-FU and 5'-DFUR. Our results indicated that PSK augmented the effects of both agents. Furthermore, when various cancer cells (human gastric cancer cell line GCIY and MKN45, and human colon cancer cell lines HCT116 and WiDr) were co-cultured with PBMCs, the addition of PSK reduced DPD mRNA expression. Using hepatocellular carcinoma cells, Oie et al (10) demonstrated that IFN-α inhibited DPD mRNA expression. Moreover, Mizutani et al (11) reported that TRAIL inhibited DPD mRNA expression in renal cell carcinoma. In contrast, Miyazaki et al (12) reported no inhibition of DPD expression.
mRNA expression when human colon cancer cell lines were incubated with IFN-α and TRAIL. Using the CD-DST system, we cultured GC1Y and HCT116 cells with IFN-α or TRAIL and observed decreased DPD mRNA expression. The mechanism by which IFN-α reduces DPD mRNA expression is unknown, but it is important due to its association with increased activity of fluoropyrimidine anticancer agents.

PSK has immunostimulatory actions and has been reported to induce the production of various chemokines and cytokines including TNF-α, IL-2 and IL-8 (8,13,14). Kitani et al (15) reported that PSK enhanced polyinosinic:polycytidylic acid (poly I:C)-induced IFN production. When we incubated PBMCs obtained from healthy subjects with PSK, increased IFN-α mRNA expression was observed in 3 of the 5 subjects examined. This result suggests that PSK-induced IFN-α expression in PBMCs may contribute to decreased DPD expression in tumor cells. In order to verify this hypothesis, more studies such as concerning the IFN-α protein expression in PBMCs are necessary, and these have to be conducted using a large number of subject to allow statistical analysis. The present study focused on DPD and further studies are ongoing to elucidate the role of IFN-α.

Since human cancer cells were examined in the present study, we used human PBMCs in the test system. Due to the limited number of PBMCs available, we were not able to test multiple samples in each experiment. We, thus, repeated the same experiment at least once to examine whether the results consistently showed the same tendency. As individual differences inevitably exist among PBMCs, as expected, there was variability in the data obtained. However, the same tendency of PSK-induced suppression of DPD mRNA expression in the presence of PBMCs was observed with all 4 cancer cell lines, suggesting a high possibility that PSK inhibits DPD mRNA expression. For TS and TP, reduced expression was observed with all 4 cancer cell lines. PSK has immunostimulatory actions and has been reported to induce the production of various chemokines and cytokines including TNF-α, IL-2 and IL-8 (8,13,14). Kitani et al (15) reported that PSK enhanced polyinosinic:polycytidylic acid (poly I:C)-induced IFN production. When we incubated PBMCs obtained from healthy subjects with PSK, increased IFN-α mRNA expression was observed in 3 of the 5 subjects examined. This result suggests that PSK-induced IFN-α expression in PBMCs may contribute to decreased DPD expression in tumor cells. In order to verify this hypothesis, more studies such as concerning the IFN-α protein expression in PBMCs are necessary, and these have to be conducted using a large number of subject to allow statistical analysis. The present study focused on DPD and further studies are ongoing to elucidate the role of IFN-α.

Recently, PSK has been reported to be an agonist of TLR2 (8) and TLR4 (16). In general, IFN-α production is considered to be triggered by TLR3, 7 and 9 (17). Recent studies have reported that IFN-α is induced also by TLR2 (18,19), suggesting a possibility that PSK induces IFN-α production via TLR2. On the other hand, PSK had no effect on TRAIL expression. There are no reports of the effects of cytokines other than IFN-α and TRAIL on DPD expression. The question of how various cytokines affect fluoropyrimidine metabolic enzymes is of great interest.

The clinical effect of combined 5-FU and IFN-α therapy remains controversial (20,21). In the study of Nagano et al (20), patients with resectable hepatocellular carcinoma (HCC) and portal vein invasion (Vp3) treated with IFN-α/5-FU as postoperative adjuvant therapy had more favorable 1- and 3-year disease-free and overall survival compared to patients not treated with IFN-α/5-FU. On the other hand, Nagano et al (20) pointed out controversial results that IFN-α alone and IFN-α/doxorubicin combination had no effect on the treatment of HCC, and IFN-α/5-FU combined chemotherapy yielded a marked effect compared to 5-FU monotherapy. Their report suggests that it is possible that IFN-α exerts some influence on the antitumor effect of fluoropyrimidines. One possible mechanism may be the suppression of DPD expression resulting in enhancement of the antitumor effect of fluoropyrimidines.

In randomized control trials on gastric cancer (3) and colorectal cancer (4), PSK when used with oral 5-FU or tegafur/uracil improved the 5-year disease-free survival compared to the monotherapy of each agent. Apart from the immunomodulatory effect, PSK has been reported to ameliorate an immunosuppressive state and to act directly on tumors inducing apoptosis and suppressing proliferation (6,7), suggesting that these complementary functions are associated with the beneficial effect observed in combination therapy. The present study results suggest that the cytokines induced by PSK act on the metabolic enzymes of fluoropyrimidines resulting in enhancement of the antitumor effect, proposing a novel mechanism of action of PSK that has not been reported hitherto. Combination of PSK and fluoropyrimidine derivatives is very useful as a therapeutic regimen that augments the effects of chemotherapies.

In conclusion, using the novel immuno-CD-DST to co-culture collagen gel-embedded tumor cells with suspended human PBMCs, we examined how PSK affects the antitumor effect of 5-FU and 5'-DFUR against gastrointestinal tumor cells. PSK enhanced the antitumor proliferative effects of 5-FU and 5'-DFUR. In studies concerning the effect of PSK on fluoropyrimidine metabolic enzymes, PSK was found to lower DPD mRNA expression. Further experiments suggest that IFN-α may inhibit DPD gene expression in tumor cells, and PSK may induce IFN-α production by PBMCs. The results obtained from the immuno-CD-DST propose the possibility that PSK acts on immunocompetent cells and induces cytokines that inhibit DPD gene expression to augment the antitumor effect of fluoropyrimidine derivatives. Immuno-CD-DST is potentially useful as an evaluation tool for drugs with immune-mediated effects. Further validation of this system is warranted.

Acknowledgements

The present study was conducted at the Shiga University of Medical Science, Shiga, Japan and Kureha Corp., Tokyo, Japan.

References


